As the pan-European STOXX Europe 600 Index edges closer to record highs, buoyed by optimism around future earnings and economic prospects, investors are increasingly on the lookout for opportunities that may be trading below their intrinsic value. In this context, identifying undervalued stocks becomes crucial, as they offer potential for growth amid a cautiously optimistic market environment where strategic selection based on fundamentals can lead to rewarding outcomes.

Name

Current Price

Fair Value (Est)

Discount (Est)

Unimot (WSE:UNT)

PLN130.00

PLN257.58

49.5%

Streamwide (ENXTPA:ALSTW)

€72.80

€142.77

49%

LINK Mobility Group Holding (OB:LINK)

NOK33.90

NOK66.31

48.9%

Kreate Group Oyj (HLSE:KREATE)

€12.55

€24.87

49.5%

KB Components (OM:KBC)

SEK41.90

SEK83.17

49.6%

Gesco (XTRA:GSC1)

€14.25

€27.99

49.1%

Fodelia Oyj (HLSE:FODELIA)

€5.40

€10.72

49.6%

Exail Technologies (ENXTPA:EXA)

€81.50

€159.26

48.8%

Dynavox Group (OM:DYVOX)

SEK102.00

SEK203.01

49.8%

Allcore (BIT:CORE)

€1.35

€2.66

49.3%

Click here to see the full list of 195 stocks from our Undervalued European Stocks Based On Cash Flows screener.

Underneath we present a selection of stocks filtered out by our screen.

Overview: Lectra SA offers industrial intelligence solutions for the fashion, automotive, and furniture markets globally, with a market cap of €969.29 million.

Operations: The company’s revenue is segmented into the following regions: €168.04 million from the Americas, €126.97 million from Asia-Pacific, and €220.55 million from EMEA (Europe, Middle East and Africa).

Estimated Discount To Fair Value: 37.1%

Lectra is trading at €25.5, significantly below its estimated fair value of €40.55, indicating it may be undervalued based on cash flows. Despite recent declines in sales and net income for the nine months ending September 2025, the company’s earnings are projected to grow substantially at 20.4% annually, outpacing the French market’s growth rate of 12%. However, its return on equity is forecasted to remain low at 11.6% in three years.

ENXTPA:LSS Discounted Cash Flow as at Jan 2026

ENXTPA:LSS Discounted Cash Flow as at Jan 2026

Overview: Aker BioMarine ASA is a biotech innovator that develops and supplies krill-derived products for consumer health and wellness worldwide, with a market cap of NOK8.66 billion.

Operations: Revenue Segments (in millions of $): Aker BioMarine’s revenue is primarily generated from its krill-derived products aimed at enhancing consumer health and wellness globally.

Story Continues